GC + IL-2

The combination of cisplatin, gemcitabine, and interleukin-2 (GC + IL-2) is a chemotherapy regimen that combines two cytotoxic agents with an immunotherapy component. This combination therapy is used in the treatment of various cancers. ## Mechanism of Action This regimen combines different therapeutic approaches: **Cisplatin** is a platinum-based chemotherapy drug that works by forming DNA crosslinks, which prevents cancer cells from dividing properly. It binds to DNA and causes the DNA strands to crosslink, which prevents cells from replicating their DNA and proceeding through cell division[3]. **Gemcitabine** is a nucleoside analog that disrupts DNA synthesis. After being metabolized inside cells, it replaces cytidine during DNA replication, which halts the process and leads to cell death. It specifically targets rapidly dividing cells, such as cancer cells[1][4]. **Interleukin-2** is an immunotherapy agent that stimulates the growth and activity of T cells and natural killer cells, enhancing the body's immune response against cancer. ## Administration The combination is typically administered intravenously: - Gemcitabine: 1,000 mg/m² on days 1 and 8 of a 21-day cycle - Cisplatin: 70 mg/m² on day 1 of a 21-day cycle[2][4] - Interleukin-2: Administered according to specific protocols For patients with reduced kidney function (creatinine clearance between 50-59 mL/min), cisplatin dosing may be adjusted to 35 mg/m² on days 1 and 8[2]. ## Treatment Duration Patients typically receive up to six cycles of the chemotherapy components (gemcitabine and cisplatin)[2]. ## Side Effects Common side effects of this combination therapy include: - Fatigue and weakness - Nausea and vomiting - Decreased blood cell counts (which can lead to increased risk of infection, bleeding, and anemia) - Fluid retention - Hearing changes or loss, including tinnitus - Kidney function changes - Heart rhythm abnormalities - Sleep disturbances - Fluid build-up in the body[4] ## Cancer Types Treated This combination has been used to treat various types of cancer, including: - Urothelial carcinoma (bladder cancer) - Lung cancer - Various carcinomas and sarcomas - Lymphomas - Germ cell tumors[1][3] The gemcitabine and cisplatin (GC) component is considered a standard therapy for metastatic urothelial carcinoma, with the addition of interleukin-2 intended to enhance anti-tumor immune responses[2].